Bioscience TechnologyA Better Understanding of How Advanced Melanoma Resists ImmunotherapyBioscience TechnologyA new study by scientists at the UCLA Jonsson Comprehensive Cancer Center could be a significant step toward understanding how certain cases … Continue reading
EurekAlert (press release) |
A protein, a ‘molecular staple’ and CRISPR to develop an Ewing sarcoma model
EurekAlert (press release) The technique, based on CRISPR and described in the pages of Stem Cell Reports, makes it possible to generate cellular models to analyse the mechanisms underlying the origin and progression of this and other diseases, as well as the search for new … |
|
Engineering human stem cells to model the kidney’s filtration barrier on a chip
Harvard School of Engineering and Applied Sciences Scanning electron micrograph of a human stem cell-derived matured podocyte with multiple primary and secondary processes extending in all directions on extracellular matrix-coated material. (Image courtesy of the Wyss Institute at Harvard University). |
Harvard School of Engineering and Applied Sciences |
Engineering human stem cells to model the kidney’s filtration barrier on a chip
Harvard School of Engineering and Applied Sciences Scanning electron micrograph of a human stem cell-derived matured podocyte with multiple primary and secondary processes extending in all directions on extracellular matrix-coated material. (Image courtesy of the Wyss Institute at Harvard University). |
|
Kristin Neuman to Speak About MPEG LA’s CRISPR Pool License at NewYorkBIO and AIPLA
Business Wire (press release) DENVER–(BUSINESS WIRE)–World licensing leader MPEG LA, LLC today announced that Kristin Neuman, MPEG LA’s Executive Director of Biotechnology Licensing, will speak at NewYorkBIO’s Annual Meeting on May 11 in New York City and at the … |
TheStreet.com |
Cancer Immunotherapy Fallout From Roche’s Bladder Cancer Failure
TheStreet.com The announcement from Roche (RHHBY) Wednesday that Tecentriq failed to prolong survival in bladder cancer is a surprising setback for the Swiss drug maker with implications and new questions for the entire cancer immunotherapy field. Will the FDA … Roche’s Tecentriq fails trial, raising questions about approvalBioPharma Dive |
|
Brammer invests in commercial-ready gene therapies
OutSourcing-Pharma.com The contract development and manufacturing organization (CDMO) said the site offers process development, clinical phase, and current Good Manufacturing Practices (cGMP) services for cell and gene therapies. “We are delighted to add an experienced … |